Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
The Chinese phase 2b obesity trial suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron but MindRank's drug was given twice a day.
Nick Paul Taylor
Jun 24, 2025 10:06am
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
Jun 23, 2025 2:30pm
Corxel, Sciwind post data as China's obesity push gathers pace
Jun 23, 2025 9:20am
Novo's injectable amycretin yet to hit weight loss plateau
Jun 23, 2025 4:29am
Lilly's amylin data impress with 11% weight loss, tolerability
Jun 16, 2025 4:55am
Novo Nordisk inks $812M Deep Apple deal to pursue obesity target
Jun 11, 2025 7:00am
